Impact of Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes

Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · Apr 2, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Individuals with type 1 diabetes who have participated in the DenSiFy (Diabetes Spine Fractures) study (NCT04064437)
• Inclusion Criteria:
• • Diagnosis of type 1 diabetes for at least 5 years;
• • Age 20 years and older.
• Exclusion Criteria:
• • Pregnancy, delivery or breastfeeding in the past 6 months;
• • Conditions associated with bone disease (significant liver disease, intestinal malabsorption other than celiac disease, organ transplant, active cancer, rheumatoid arthritis, hyperthyroidism, hypothyroidism with abnormal TSH, hyperparathyroidism, hypoparathyroidism, hypogonadism, acromegaly, Cushing syndrome, adrenal insufficiency);
• • Any of these medications since the first DenSiFy study visit : biphosphonates, teriparatide, denosumab, calcitonin, glucocorticoids ≥ 7,5 mg prednisone/day or equivalency ≥ 3 months, aromatase inhibitors, antiandrogens, antiepileptic drugs, anticoagulants, thiazolidinediones;
• • Inability to consent.
• • Healthy controls who have participated in the DenSiFy (Diabetes Spine Fractures) study (NCT04064437)
• Inclusion Criteria:
• • Age 20 years and older.
• Exclusion Criteria :
• * As above (as individuals with diabetes), and :
• • Diagnosis of diabetes or prediabetes;
• • Celiac disease;
• • Chronic kidney disease (CrCl \< 60 mL/min).